炎症
医学
免疫学
疾病
类风湿性关节炎
趋化因子
促炎细胞因子
炎症性肠病
糖尿病
肿瘤坏死因子α
哮喘
癌症
生物信息学
生物
内科学
内分泌学
作者
Durgaprasad Laveti,Manoj Kumar,Hemalatha Rajkumar,Ramakrishna Sistla,V.G.M. Naidu,Venu Talla,Vinod Verma,Navrinder Kaur,Ravinder Nagpal
出处
期刊:Inflammation and Allergy - Drug Targets
[Bentham Science]
日期:2013-09-01
卷期号:12 (5): 349-361
被引量:284
标识
DOI:10.2174/18715281113129990053
摘要
Inflammation is viewed as one of the major causes for the development of different diseases like cancer, cardiovascular disease, diabetes, obesity, osteoporosis, rheumatoid arthritis, inflammatory bowel disease, asthma, and CNS related diseases such as depression and parkinson's disease; and this fervent phenomenon provides space for understanding different inflammatory markers. Increasing evidences have elucidated the outcome of inflammatory pathways dysregulation resulting in many symptoms of chronic diseases. The detection of transcription factors such as nuclear factor kappa-B (NF-ΚB), STAT and their gene products such as COX-2, cytokines, chemokines and chemokine receptors has laid molecular foundation for the important role of inflammation in chronic diseases in which the NF-ΚB is reported as a major mediator which makes a possible way for the development of new therapeutic approaches using synthetic and natural compounds that might eventually decrease the prevalence of these diseases. Even if many inflammatory markers like TNF-α, IL-1, IL-6, IL-8 and C-reactive protein (CRP) are reported to be the major key factors with proved role in several inflammatory diseases, IL-1 and TNF-α are the important cytokines that can induce the expression of NF-ΚB which is the potential target in these inflammatory diseases. This review aims to explore and summarize that how some drugs and natural compounds show their modulatory activity in inflammatory pathways and chronic inflammatory markers in these inflammatory diseases. Keywords: Asthma, cancer, cardiovascular disease, CNS disorders, diabetes, inflammation, inflammatory markers, obesity.
科研通智能强力驱动
Strongly Powered by AbleSci AI